Skip to Main Content

Author Details

Christoph Reinhard
Lilly Research Laboratories
1992
38
27
Jake Y. Chen (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
36745526Correction: Separation of low and high grade colon and rectum carcinoma by eukaryotic translation initiation factors 1, 5 and 6.Oncotarget2023
36745526Correction: Separation of low and high grade colon and rectum carcinoma by eukaryotic translation initiation factors 1, 5 and 6.Oncotarget2023
33920536Precision Oncology Beyond Genomics: The Future Is Here-It Is Just Not Evenly Distributed.Cells2021
33920536Precision Oncology Beyond Genomics: The Future Is Here-It Is Just Not Evenly Distributed.Cells2021
32612211Molecular dissection of CRC primary tumors and their matched liver metastases reveals critical role of immune microenvironment, EMT and angiogenesis in cancer metastasis.Sci Rep2020
32709976Author Correction: Evaluation of molecular subtypes and clonal selection during establishment of patient-derived tumor xenografts from gastric adenocarcinoma.Commun Biol2020
32647357Evaluation of molecular subtypes and clonal selection during establishment of patient-derived tumor xenografts from gastric adenocarcinoma.Commun Biol2020
32612211Molecular dissection of CRC primary tumors and their matched liver metastases reveals critical role of immune microenvironment, EMT and angiogenesis in cancer metastasis.Sci Rep2020
32709976Author Correction: Evaluation of molecular subtypes and clonal selection during establishment of patient-derived tumor xenografts from gastric adenocarcinoma.Commun Biol2020
32647357Evaluation of molecular subtypes and clonal selection during establishment of patient-derived tumor xenografts from gastric adenocarcinoma.Commun Biol2020
30373917Aurora A Kinase Inhibition Is Synthetic Lethal with Loss of the <i>RB1</i> Tumor Suppressor Gene.Cancer Discov2019
31653970Genomic characterization of intrinsic and acquired resistance to cetuximab in colorectal cancer patients.Sci Rep2019
30373917Aurora A Kinase Inhibition Is Synthetic Lethal with Loss of the <i>RB1</i> Tumor Suppressor Gene.Cancer Discov2019
31530649Aurora A-Selective Inhibitor LY3295668 Leads to Dominant Mitotic Arrest, Apoptosis in Cancer Cells, and Shows Potent Preclinical Antitumor Efficacy.Mol Cancer Ther2019
31653970Genomic characterization of intrinsic and acquired resistance to cetuximab in colorectal cancer patients.Sci Rep2019
31530649Aurora A-Selective Inhibitor LY3295668 Leads to Dominant Mitotic Arrest, Apoptosis in Cancer Cells, and Shows Potent Preclinical Antitumor Efficacy.Mol Cancer Ther2019
30077122Influence of eukaryotic translation initiation factor 6 on non-small cell lung cancer development and progression.Eur J Cancer2018
30077122Influence of eukaryotic translation initiation factor 6 on non-small cell lung cancer development and progression.Eur J Cancer2018
29254159Separation of low and high grade colon and rectum carcinoma by eukaryotic translation initiation factors 1, 5 and 6.Oncotarget2017
29254159Separation of low and high grade colon and rectum carcinoma by eukaryotic translation initiation factors 1, 5 and 6.Oncotarget2017
29232554Genomic Aberrations that Activate D-type Cyclins Are Associated with Enhanced Sensitivity to the CDK4 and CDK6 Inhibitor Abemaciclib.Cancer Cell2017
28186126Molecular dissection of colorectal cancer in pre-clinical models identifies biomarkers predicting sensitivity to EGFR inhibitors.Nat Commun2017
28186126Molecular dissection of colorectal cancer in pre-clinical models identifies biomarkers predicting sensitivity to EGFR inhibitors.Nat Commun2017
29232554Genomic Aberrations that Activate D-type Cyclins Are Associated with Enhanced Sensitivity to the CDK4 and CDK6 Inhibitor Abemaciclib.Cancer Cell2017
27160712Genomic alterations and molecular subtypes of gastric cancers in Asians.Chin J Cancer2016
27233291Assay Establishment and Validation of a High-Throughput Screening Platform for Three-Dimensional Patient-Derived Colon Cancer Organoid Cultures.J Biomol Screen2016
27160712Genomic alterations and molecular subtypes of gastric cancers in Asians.Chin J Cancer2016
27233291Assay Establishment and Validation of a High-Throughput Screening Platform for Three-Dimensional Patient-Derived Colon Cancer Organoid Cultures.J Biomol Screen2016
25583476Mutational landscape of gastric adenocarcinoma in Chinese: implications for prognosis and therapy.Proc Natl Acad Sci U S A2015
25583476Mutational landscape of gastric adenocarcinoma in Chinese: implications for prognosis and therapy.Proc Natl Acad Sci U S A2015
25894828Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes.Nat Med2015
25894828Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes.Nat Med2015
25189529Whole-genome sequencing of asian lung cancers: second-hand smoke unlikely to be responsible for higher incidence of lung cancer among Asian never-smokers.Cancer Res2014
25407104Genomic landscape and genetic heterogeneity in gastric adenocarcinoma revealed by whole-genome sequencing.Nat Commun2014
25189529Whole-genome sequencing of asian lung cancers: second-hand smoke unlikely to be responsible for higher incidence of lung cancer among Asian never-smokers.Cancer Res2014
25407104Genomic landscape and genetic heterogeneity in gastric adenocarcinoma revealed by whole-genome sequencing.Nat Commun2014
23788652Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma.Genome Res2013
23788652Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma.Genome Res2013
22634754Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma.Nat Genet2012
22634754Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma.Nat Genet2012
23079560Network expansion and pathway enrichment analysis towards biologically significant findings from microarrays.J Integr Bioinform2012
23079560Network expansion and pathway enrichment analysis towards biologically significant findings from microarrays.J Integr Bioinform2012
12802020TSG101 interaction with HRS mediates endosomal trafficking and receptor down-regulation.Proc Natl Acad Sci U S A2003
12802020TSG101 interaction with HRS mediates endosomal trafficking and receptor down-regulation.Proc Natl Acad Sci U S A2003
12417719Normal p53 function in primary cells deficient for Siah genes.Mol Cell Biol2002
12417719Normal p53 function in primary cells deficient for Siah genes.Mol Cell Biol2002
11433294PAR-1 is a Dishevelled-associated kinase and a positive regulator of Wnt signalling.Nat Cell Biol2001
11752446Elevated expression of axin2 and hnkd mRNA provides evidence that Wnt/beta -catenin signaling is activated in human colon tumors.Proc Natl Acad Sci U S A2001
11746500Modulation of human cytomegalovirus immediate-early gene enhancer by mitogen-activated protein kinase kinase kinase-1.J Cell Biochem2001
11433294PAR-1 is a Dishevelled-associated kinase and a positive regulator of Wnt signalling.Nat Cell Biol2001
  • 1 - 50 of 76

Recommended Authors

Sanford Burnham Prebys Medical Discovery Institute
Career Start Year 2015
Number of shared co-authors 0
The First Affiliated Hospital of Guangdong Pharmaceutical University
Career Start Year 2005
Number of shared co-authors 0
University of Nebraska Medical Center
Career Start Year 2004
Number of shared co-authors 0
Institute for Research in Immunology and Cancer (IRIC)
Career Start Year 2004
Number of shared co-authors 0
The University of Hong Kong
Career Start Year 2003
Number of shared co-authors 0
Cancer Stem Cell Research Center, Samsung Biomedical Research Institute
Career Start Year 2001
Number of shared co-authors 6
Aier Eye Hospital of Wuhan University
Career Start Year 2001
Number of shared co-authors 2
Research Institute, National Cancer Center
Career Start Year 2000
Number of shared co-authors 2
IRIC - University of Montreal
Career Start Year 1998
Number of shared co-authors 0
The University of Texas MD Anderson Cancer Center
Career Start Year 1998
Number of shared co-authors 0
Quantitative Biosciences Institute (QBI), University of California San Francisco
Career Start Year 1996
Number of shared co-authors 0
University of Georgia
Career Start Year 1994
Number of shared co-authors 0
University of South Carolina
Career Start Year 1993
Number of shared co-authors 1
Case Western Reserve University School of Medicine
Career Start Year 1993
Number of shared co-authors 0
St Jude Children's Research Hospital
Career Start Year 1991
Number of shared co-authors 0
The University of Texas MD Anderson Cancer Center
Career Start Year 1988
Number of shared co-authors 2
University of California San Diego
Career Start Year 1988
Number of shared co-authors 2
Candiolo Cancer Institute, Fondazione del Piemonte per l'Oncologia (FPO) - IRCCS
Career Start Year 1988
Number of shared co-authors 0
Rutgers New Jersey Medical School
Career Start Year 1987
Number of shared co-authors 0
Broad Institute of MIT and Harvard, USA Dana-Farber Cancer Institute
Career Start Year 1987
Number of shared co-authors 2
Netherlands Cancer Institute
Career Start Year 1987
Number of shared co-authors 0
The University of Texas MD Anderson Cancer Center
Career Start Year 1987
Number of shared co-authors 0
Laboratorio Nazionale-Consorzio Interuniversitario per le Biotecnologie
Career Start Year 1987
Number of shared co-authors 0
Hospital for Sick Children, University of Toronto
Career Start Year 1985
Number of shared co-authors 0
Moores Cancer Center, University of California San Diego
Career Start Year 1984
Number of shared co-authors 1
Institute for Research in Immunology and Cancer
Career Start Year 1982
Number of shared co-authors 0
Cancer Center, Sanford Burnham Prebys Medical Discovery Institute
Career Start Year 1981
Number of shared co-authors 1
Knight Cancer Institute, Oregon Health and Sciences University
Career Start Year 1976
Number of shared co-authors 2
Frederick National Laboratory for Cancer Research
Career Start Year 1975
Number of shared co-authors 1
Salk Institute for Biological Studies
Career Start Year 1968
Number of shared co-authors 1

Collaborators

Institute of Pathology, Medical University of Innsbruck
Co-authored papers 5
Co-authored papers 4
Samsung Medical Center, Sungkyunkwan University School of Medicine
Co-authored papers 3
Institute of Pathology, Medical University of Graz
Co-authored papers 3
Lilly Research Laboratories
Co-authored papers 3
Merck & Co., Inc.
Co-authored papers 3
Jilin University
Co-authored papers 2
Samsung Medical Center, Sungkyunkwan University School of Medicine
Co-authored papers 2
ShanghaiBio Corporation
Co-authored papers 2
Co-authored papers 2
Seoul National University College of Medicine
Co-authored papers 2
Busan Paik Hospital, Inje University
Co-authored papers 2
Co-authored papers 2
Lilly Research Laboratories
Co-authored papers 2
Zhongnan Hospital of Wuhan University
Co-authored papers 2
University of Texas
Co-authored papers 1
Co-authored papers 1
Co-authored papers 1
Co-authored papers 1
Research Institute, National Cancer Center
Co-authored papers 1
Co-authored papers 1
Samsung Medical Center, Sungkyunkwan University School
Co-authored papers 1
Memorial Sloan-Kettering Cancer Center
Co-authored papers 1
University of Alabama at Birmingham
Co-authored papers 1
Co-authored papers 1
Peter MacCallum Cancer Centre
Co-authored papers 1
Children's Hospital, Zhejiang University School of Medicine
Co-authored papers 1
Bristol Royal Hospital for Children, University Hospital Bristol NHS Trust
Co-authored papers 1
Max Planck Institute for Molecular Genetics
Co-authored papers 1
Ludwig Institute for Cancer Research, University of California San Diego
Co-authored papers 1